Form 8-K - Current report:
SEC Accession No. 0000950170-24-093314
Filing Date
2024-08-08
Accepted
2024-08-08 07:15:08
Documents
12
Period of Report
2024-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cgem-20240808.htm   iXBRL 8-K 40221
2 EX-99.1 cgem-ex99_1.htm EX-99.1 168567
  Complete submission text file 0000950170-24-093314.txt   339706

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20240808.xsd EX-101.SCH 25882
14 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20240808_htm.xml XML 4889
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813867811 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39856 | Film No.: 241186023
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)